コンテンツへスキップ
Merck

Piroxicam induced pulmonary infiltrates and eosinophilia.

The Journal of rheumatology (1994-08-01)
P Pfitzenmeyer, M Meier, P Zuck, G Peiffer, P Masson, A Turcu, F Piard, P Camus
要旨

We describe 2 patients who developed pulmonary infiltrates while being treated with piroxicam. There was no satisfactory explanation other than drug induced lung disease for their illness. They had no exposure to pneumotoxic drugs or aerocontaminants. Microorganisms were not cultured in sputum or bronchoaveolar lavage. There was no underlying illness with possible lung involvement. Pulmonary infiltrates developed during piroxicam therapy, disappeared after drug withdrawal and recurred following rechallenge.

材料
製品番号
ブランド
製品内容

Sigma-Aldrich
ピロキシカム, ≥98% (TLC)
USP
ピロキシカム, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
ピロキシカム, meets USP testing specifications
システム適合性用ピロキシカム, European Pharmacopoeia (EP) Reference Standard
ピロキシカム, European Pharmacopoeia (EP) Reference Standard